Miniatura

Fitxers

827631.pdf (4.75 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-08-01

Llicència de publicació

cc-by (c) Rubió-Casadevall, Jordi et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/208761

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fonc.2023.1226939

Resum

Objectives: The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are medically unfit for cisplatin-based (PT) chemotherapy. Materials and methods: This retrospective, non-interventional study involved 16 centers in Spain. Inclusion criteria were to have started receiving ERBITAX regimen from January 2012 to December 2018; histologically confirmed SCCHN including oral cavity, oropharynx, hypopharynx, and larynx; age ≥18 years; and platinum (PT) chemotherapy ineligibility due to performance status, comorbidities, high accumulated dose of PT, or PT refractoriness. Results: A total of 531 patients from 16 hospitals in Spain were enrolled. The median age was 66 years, 82.7% were male, and 83.5% were current/former smokers. Patients were ineligible to receive PT due to ECOG 2 (50.3%), comorbidities (32%), PT cumulative dose ≥ 225 mg/m2 (10.5%), or PT refractoriness (7.2%). Response rate was 37.7%. Median duration of response was 5.6 months (95% CI: 4.4-6.6). With a median follow-up of 8.7 months (95% CI: 7.7-10.2), median PFS and OS were 4.5 months (95% CI: 3.9-5.0) and 8.9 months (95% CI: 7.8-10.3), respectively. Patients treated with immunotherapy after ERBITAX had better OS with a median of 29.8 months compared to 13.8 months for those who received other treatments. The most common grade ≥ 3 toxicities were acne-like rash in 36 patients (6.8%) and oral mucositis in 8 patients (1.5%). Five (0.9%) patients experienced grade ≥ 3 febrile neutropenia. Conclusion: This study confirms the real-world efficacy and tolerability of ERBITAX as first-line treatment in recurrent/metastatic SCCHN when PT is not feasible. Immunotherapy after treatment with ERBITAX showed remarkable promising survival, despite potential selection bias.

Matèries

Malalts hospitalitzats, Càncer de cap, Càncer de coll, Anticossos monoclonals

Matèries (anglès)

Hospital patients, Head cancer, Neck cancer, Monoclonal antibodies

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MESÍA NIN, Ricard, RUBIÓ-CASADEVALL, Jordi, CIRAUQUI CIRAUQUI, Beatriz, MARTINEZ TRUFERO, Javier, PLANA SERRAHIMA, Maria, GARCÍA CASTAÑO, Almudena, CARRAL MASEDA, Alberto, IGLESIAS DOCAMPO, Lara, PÉREZ SEGURA, Pedro, CEBALLOS LENZA, Isaac, GUTIÉRREZ CALDERÓN, Vanesa, FUSTER SALVÀ, José, PENA ÁLVAREZ, Carolina, HERNANDEZ, Irene, BARCO MORILLO, Edel del, CHAVES CONDE, Manuel, MARTÍNEZ GALÁN, Joaquina, DURÁN SÁNCHEZ, Marisa, QUIROGA GARCIA, Vanesa, ORTEGA, Eugenia. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. _Frontiers In Oncology_. 2023. Vol. 13. [consulta: 28 de gener de 2026]. ISSN: 2234-943X. [Disponible a: https://hdl.handle.net/2445/208761]

Exportar metadades

JSON - METS

Compartir registre